CVS Health Corp (CVS) Receives Average Rating of “Buy” from Brokerages

CVS Health Corp (NYSE:CVS) has been assigned a consensus rating of “Buy” from the twenty-four ratings firms that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $87.55.

A number of equities research analysts have recently weighed in on CVS shares. Leerink Swann reiterated an “outperform” rating and issued a $85.00 price target (down from $90.00) on shares of CVS Health in a report on Tuesday, November 7th. Raymond James Financial upgraded CVS Health from an “outperform” rating to a “strong-buy” rating and set a $90.00 price target for the company in a report on Thursday, January 4th. They noted that the move was a valuation call. Citigroup set a $76.00 price target on CVS Health and gave the company a “hold” rating in a report on Monday, December 4th. Needham & Company LLC upped their price objective on CVS Health from $79.00 to $85.00 and gave the stock a “buy” rating in a research note on Monday, December 4th. Finally, Jefferies Group set a $76.00 price objective on CVS Health and gave the stock a “hold” rating in a research note on Monday, December 4th.

In other news, EVP Lisa Bisaccia sold 29,445 shares of the company’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total value of $2,208,375.00. Following the completion of the sale, the executive vice president now owns 15,556 shares in the company, valued at $1,166,700. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.61% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Sawtooth Solutions LLC boosted its stake in shares of CVS Health by 12.6% during the 4th quarter. Sawtooth Solutions LLC now owns 8,110 shares of the pharmacy operator’s stock worth $588,000 after acquiring an additional 908 shares in the last quarter. We Are One Seven LLC bought a new stake in shares of CVS Health during the 4th quarter worth about $805,000. Salem Investment Counselors Inc. boosted its stake in shares of CVS Health by 20.2% during the 4th quarter. Salem Investment Counselors Inc. now owns 81,660 shares of the pharmacy operator’s stock worth $5,920,000 after acquiring an additional 13,726 shares in the last quarter. Compagnie Lombard Odier SCmA boosted its stake in shares of CVS Health by 14.0% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 9,936 shares of the pharmacy operator’s stock worth $721,000 after acquiring an additional 1,221 shares in the last quarter. Finally, First Commonwealth Financial Corp PA boosted its stake in shares of CVS Health by 12.0% during the 4th quarter. First Commonwealth Financial Corp PA now owns 12,569 shares of the pharmacy operator’s stock worth $911,000 after acquiring an additional 1,343 shares in the last quarter. 83.23% of the stock is currently owned by institutional investors.

CVS Health (CVS) traded down $1.32 during mid-day trading on Tuesday, reaching $70.58. The company’s stock had a trading volume of 1,909,967 shares, compared to its average volume of 8,886,878. The company has a quick ratio of 0.52, a current ratio of 1.02 and a debt-to-equity ratio of 0.59. CVS Health has a 52 week low of $66.45 and a 52 week high of $84.00. The stock has a market cap of $71,680.00, a P/E ratio of 10.94, a PEG ratio of 1.22 and a beta of 0.92.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.88 by $0.04. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. The business had revenue of $48.39 billion during the quarter, compared to the consensus estimate of $47.54 billion. During the same period in the previous year, the business earned $1.71 EPS. The business’s quarterly revenue was up 5.3% on a year-over-year basis. equities research analysts anticipate that CVS Health will post 6.38 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, February 2nd. Stockholders of record on Wednesday, January 24th were issued a $0.50 dividend. The ex-dividend date was Tuesday, January 23rd. This represents a $2.00 annualized dividend and a dividend yield of 2.83%. CVS Health’s dividend payout ratio (DPR) is 30.91%.

TRADEMARK VIOLATION NOTICE: This article was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.thelincolnianonline.com/2018/02/20/cvs-health-corp-cvs-receives-average-rating-of-buy-from-brokerages.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply